T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update

Novel cellular immunotherapies such as T-cell engaging antibodies (TCEAbs) are changing the landscape of treatment for diffuse large B cell lymphoma (DLBCL), especially in the relapsed/refractory (R/R) setting. TCEAbs harness the power of the host immune system to induce killing of tumor cells by bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Balendran, Shalini, Tam, Constantine, Ku, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647650/
https://www.ncbi.nlm.nih.gov/pubmed/37959202
http://dx.doi.org/10.3390/jcm12216737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647650/
https://www.ncbi.nlm.nih.gov/pubmed/37959202
http://dx.doi.org/10.3390/jcm12216737

Ejemplares similares